选择性雌激素受体降解剂在乳腺癌治疗中的研究进展  

Application of targeted estrogen receptor depressants in the treatment of breast cancer

作　　者：郑菲 徐成[1] 陈文敏 王苑郦 ZHENG Fei;XU Cheng;CHEN Wenmin;WANG Yuanli(School of Life Sciences and Biopharmaceutical,Shenyang Pharmaceutical University,Shengyang 110016,China;Ganlee Co,Ltd,Beijing 101100,China)

机构地区：[1]沈阳药科大学生命科学与生物制药学院,沈阳110016 [2]甘李药业股份有限公司,北京101100

出　　处：《药学前沿》2025年第3期516-524,共9页China Pharmacist

摘　　要：乳腺癌是全世界女性最常见的恶性肿瘤,其中雌激素受体(ER)α阳性乳腺癌约占70%。迄今为止,治疗ERα阳性乳腺癌的首要干预措施是传统内分泌治疗,但该治疗引起的耐药问题仍然是乳腺癌长期治疗的主要障碍。为了克服此弊端,口服ER降解剂以及新兴的蛋白降解药物技术相继问世,本综述将重点总结靶向降解ERα的最新药物研究进展,为后续治疗ERα阳性乳腺癌的药物研发提供参考。Breast cancer is the most common malignant tumor in women worldwide,and estrogen receptor(ER)α-positive breast cancer accounts for about 70%.To date,the primary intervention for the treatment of ERα-positive breast cancer is traditional endocrine therapy,but the problem of drug resistance caused by this treatment remains a major obstacle to long-term treatment of breast cancer.In order to overcome this disadvantage,oral estrogen receptor degraders and emerging protein degrading drug technologies have been developed.This review will focus on the latest research progress of targeted ERα degradation drugs,so as to provide reference for the subsequent development of drugs for the treatment of ERα-positive breast cancer.

关 键 词：乳腺癌 雌激素受体 内分泌治疗 选择性雌激素受体降解剂 蛋白降解靶向嵌合体 

分 类 号：R966[医药卫生—药理学]